Abstract 262P
Background
Gestational trophoblastic tumors (GTTs) are the malignant forms of gestational trophoblastic diseases. They always follow a pregnancy, most often molar. The diagnosis of TTG is based on an abnormal course of HCG (chorionic gonadotropin hormone) and / or signs of ultrasound invasion and/or histological confirmation.
Methods
it is a retrospective study of 29 cases of GTT collected at the medical oncology department of Hassan II University Hospital-Fez, over a period of 7 years from January 2010 to December 2016.
Results
The average age was 35 years old. Sixty-five percent (65%) of our patients were pauciparous. The causal pregnancy was in 83% of cases a molar pregnancy. The staging of patients revealed pulmonary metastases in 67% of cases, liver in 19% of cases, renal in 7% of cases and cerebral in 7% of cases. Nine patients (31 %) underwent hysterectomy, with postoperative chemotherapy for 8 patients. Fifty-two percent (52%) were at high risk while 48% were low risk. Low risk patients received methotrexate-based monochemotherapy, and HCG hormone became negative after an average of 6.5 cycles. High risk patients received a polychemotherapy with differents protocols used; EMA-CO, BEP, or Cisplatin-Etoposid-MTX protocol, after an average of 3.28 cycles, the HCG hormone became negative. Eighty-six percent of our patients benefited from clinical and biological monitoring. The evolution of our patients was marked by a complete clinical and biological remission in 89.65% of patients, after an average of 12 weeks. The median survival was 76.4 ± 2.7 months, after a median follow-up of 29.78 months.
Conclusions
Malignant gestational trophoblastic tumors are a rare and challenging disease with heavy psychosocial impact hat affect the young woman who has not only had a pregnancy loss but also may be faced with a life-threatening illness. More understanding of risk factors, carcinogenesis and management is required to improve the outcome of thes patients. larger studies are still needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract